First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

BACKGROUND: HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations. METHODS: This was a multicenter phase 1 study. HL-085 was administered twice daily in a standard 3 + 3 dose-esc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuan, Luo, Zhiguo, Chen, Jing, Chen, Yu, Ji, Dongmei, Fan, Li, Chen, Ling, Zhao, Qian, Hu, Pei, Sun, Peng, Jia, Zhongwei, Guo, Jun, Si, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814429/
https://www.ncbi.nlm.nih.gov/pubmed/36600247
http://dx.doi.org/10.1186/s12916-022-02669-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814429/
https://www.ncbi.nlm.nih.gov/pubmed/36600247
http://dx.doi.org/10.1186/s12916-022-02669-7

Ejemplares similares